Q-omics provides the consensus-scored GTPBP8 profile across patient tissues and cancer cell-line models. GTPBP8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GTPBP8 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, GTPBP8 RNA expression shows 19,601 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where GTPBP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTPBP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTPBP8 survival associations across molecular data types. GTPBP8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTPBP8 RNA expression–survival associations across cancer types. High GTPBP8 expression shows unfavorable associations in LIHC, ACC, KICH, UCEC and LUAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GTPBP8 RNA expression.
This table summarizes GTPBP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GTPBP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTPBP8 shows higher tumor expression in HNSC, LIHC, LUSC, BLCA, CHOL and LUAD. The HNSC box plot shows higher GTPBP8 RNA expression in tumor versus normal tissue (log2 FC = +0.593, t-test p = .004).
This table shows molecular features associated with GTPBP8 in patient tissues and cancer cell lines. In patient samples, GTPBP8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GTPBP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
